Loading...

SOHO 2026 Annual Meeting

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Poster Session

Thumbnail for Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

CLL - 580

Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

Jude Ossai

Poster Presenter: Jude Ossai

Thumbnail for Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge

CLL - 620

Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge

Adela Perolla

Poster Presenter: Adela Perolla

Thumbnail for Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

CLL - 630

Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pool Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetics/Molecular Risks

CLL - 662

Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pool Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetics/Molecular Risks

Jun Chih Wang

Poster Presenter: Jun Chih Wang

Thumbnail for Frailty in Chronic Lymphocytic Leukemia: Evidence From the 2017-2022 Nationwide Inpatient Sample of the United States

CLL - 689

Frailty in Chronic Lymphocytic Leukemia: Evidence From the 2017-2022 Nationwide Inpatient Sample of the United States

Preetham Ezhilarasu

Poster Presenter: Preetham Ezhilarasu

Thumbnail for BTK Inhibitors Are Associated With Significantly Lower Hospitalization and Reduced Cardiovascular Morbidity Compared With Venetoclax-Based Regimens in CLL/SLL: A Propensity Score-Matched, Real-World Analysis

CLL - 693

BTK Inhibitors Are Associated With Significantly Lower Hospitalization and Reduced Cardiovascular Morbidity Compared With Venetoclax-Based Regimens in CLL/SLL: A Propensity Score-Matched, Real-World Analysis

Ekow Pinkrah

Poster Presenter: Ekow Pinkrah

Thumbnail for Risk of Tumor Lysis Syndrome (TLS) Among Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Treated With Venetoclax: A Real-World Study

CLL - 737

Risk of Tumor Lysis Syndrome (TLS) Among Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Treated With Venetoclax: A Real-World Study

Alessandra Ferrajoli

Poster Presenter: Alessandra Ferrajoli

Thumbnail for Pirtobrutinib's Cardiac Adverse Reactions: An Early Pharmacovigilance Study

CLL - 763

Pirtobrutinib's Cardiac Adverse Reactions: An Early Pharmacovigilance Study

Maroun Ibrahim

Poster Presenter: Maroun Ibrahim

Thumbnail for Micro-Dosed Obinutuzumab: A Novel Debulking Strategy in a Rare Case of Leukostasis From Chronic Lymphocytic Leukemia

CLL - 787

Micro-Dosed Obinutuzumab: A Novel Debulking Strategy in a Rare Case of Leukostasis From Chronic Lymphocytic Leukemia

Ahmed Qaedi

Poster Presenter: Ahmed Qaedi